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Objetivos: A glândula lacrimal e a conjuntiva são os tecidos oculares
primariamente afetados pela doença enxerto-versus-hospedeiro (DEVH)
crônica, e seu envolvimento clínico é caracterizado por ceratoconjuntivite
seca (CCS). Os objetivos deste estudo foram os de avaliar a freqüência
dos sintomas e sinais de CCS em pacientes submetidos ao transplante
de medula óssea (TMO) e identificar a população celular por análise
imuno-histoquímica de biópsias da conjuntiva e glândula lacrimal desses
pacientes, correlacionando esses achados com o quadro clínico ocular.
Métodos: Quarenta e sete pacientes foram classificados em dois grupos:
Grupo I, pacientes com DEVH ocular, submetidos ao TMO alogênico e
Grupo II, pacientes sem DEVH ocular, submetidos ao TMO alogênico e
autólogo. Exame ocular completo, incluindo testes clínicos da função
lacrimal, e biópsias de conjuntiva e glândula lacrimal foram realizadas nos
períodos pré e pós-transplante. Estudou-se a população celular, por meio
de análise imuno-histoquímica das biópsias, utilizando um painel de
anticorpos monoclonais. Resultados: Dos 28 (82,4%) pacientes com
DEVH crônica, 13 (46,4%) apresentaram DEVH ocular. Dos seis pacientes
sem DEVH, um (16,7%) apresentou DEVH ocular. Nenhum paciente
submetido a TMO autólogo apresentou DEVH ocular e 14 (41,2%) dos
34 pacientes com TMO alogênico desenvolveram DEVH ocular. Todos
os pacientes com DEVH ocular (Grupo I) apresentaram sintomas e os mais
freqüentes foram ardor, sensação de corpo estranho, visão borrada e
secura ocular. O teste de rosa bengala foi um dos mais sensíveis e o exame
biomicroscópico foi considerado muito útil na avaliação das alterações
conjuntivais e corneanas, as quais estavam sempre presentes nos
pacientes com DEVH ocular deste estudo. Na conjuntiva e na glândula
lacrimal dos pacientes sem DEVH ocular não houve reação imunológica
significante, concordando com os testes de função lacrimal. Houve
aumento da população de linfócitos T, dos linfócitos T auxiliadores (Th/i)
e linfócitos T supressores-citotóxicos (Ts/c) após o transplante na conjuntiva
e glândula lacrimal de pacientes com DEVH ocular. Conclusões: Pacien-
tes submetidos ao TMO alogênico podem desenvolver DEVH ocular,
caracterizado por ceratoconjuntivite seca. O estudo imuno-histoquímico
de biópsias da conjuntiva e glândula lacrimal desses pacientes sugere
que esses tecidos são alvo de reação imunológica mediada pelos
linfócitos T.
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INTRODUCTION
Bone marrow transplantation (BMT) has been increasingly
used in the treatment of severe hematological malignancies
and other malignant diseases, aplastic anemia and immuno-
deficiencies. Patients either receive autologous marrow taken
while in remission and stored for reinfusion at a later date, or
matched donor marrow either from a relative or an unrelated
donor. Prior to infusion of the marrow, the patients receive
high-dose chemotherapy alone or in combination with total
body irradiation (TBI) to eradicate all host malignant tissue
and minimize rejection of the donor marrow(1).
Despite the overall success of this approach, a number of
serious and potentially fatal complications may occur follow-
ing transplantation. The major noninfective complication of
allogeneic BMT is graft-versus-host disease (GVHD), in
which the lymphocytes of the immunocompetent donor mar-
row mount an immunological attack on the now immunoincom-
petent host. This disease affects principally the skin, eyes and
gastrointestinal tract and may be fatal(2). The clinicopatho-
logic features resemble the naturally occurring autoimmune
connective tissue disorders (Sjögren-like syndrome) and pre-
sent considerable variability in the mode of onset, the invol-
ved organ systems and the rate of progression (3).
Two forms of GVHD have been described: the term acute
GVHD is used to describe a distinctive syndrome of dermati-
tis, hepatitis and enteritis developing within 100 days of allo-
geneic BMT. Chronic GVHD is a more pleiotropic syndrome
that develops after day 100(4). Patients submitted to autolo-
gous BMT do not develop chronic GVHD.
Ocular involvement in GVHD presents as keratoconjuncti-
vitis sicca (KCS) consisting of punctate keratitis, persistent
corneal epithelial defects and sterile stromal ulceration (5). The
prevalence of ocular GVHD in patients with chronic GVHD is
described in the literature as being between 60%(6) and
81.8%(1). There is a correlation between poor prognosis in
systemic GVHD and the occurrence of ocular GVHD(6).
Other causes of dry eye after BMT could be attributed to
total body irradiation and ocular toxicity of chemotherapy(7).
Histological studies in patients with chronic GVHD indicate
similarities with Sjögren’s syndrome: presence of inflammato-
ry cells in the conjunctiva and cornea, as well as inflammatory
and destructive ductile involvement in lacrimal glands(8).
The objectives of this study are:
1)  To identify and evaluate the frequency of patients with
ocular GVHD in bone marrow transplant recipients, their sym-
ptoms and signs and the value of lacrimal function clinical
tests for diagnosis of dry eye in these patients.
2) To identify the cellular phenotype of conjunctival and
lacrimal gland inflammatory infiltrates by immunohistochemis-
try in this population and correlate them with clinical findings.
The incidence of GVHD tends to increase with the use of
BMT as an alternative to the treatment of neoplasms, and a
reasonable number of younger patients, surviving the trans-
plant and its complications could present dry eyes. We under-
stand that the clinical and immunohistochemical ocular altera-
tions are of great value not only for the characterization of
lacrimal dysfunction but also for the understanding of the
immunopathologic mechanisms of systemic GVHD.
METHODS
Sixty-five patients who underwent BMT between Septem-
ber 1994 and December 1995, were examined at the Department
of Ophthalmology, Universidade Federal de São Paulo. Pa-
tients were referred to us by the Bone Marrow Transplanta-
tion Sector, Fundação Pró-Sangue Hemocentro of São Paulo.
The criteria for patient eligibility were age over 10 years,
written consent to participate in the study, no previous ocular
diseases and no acute conjunctival or corneal infection on
clinical examination. Of the 65 patients fulfilling the inclusion
criteria, 15 were subsequently excluded due to problems rela-
ted to GVHD morbidity, such as hematological and infectious
complications and 3 who refused further ocular biopsy. As a
result of this selection, 47 patients were submitted to ocular
examination, conjunctiva and lacrimal gland biopsies. In 19
patients it was possible to perform two biopsies of the conjun-
ctiva and lacrimal gland, one before and the other after BMT.
Patients were divided into groups, according to the presence
or absence of ocular GVHD as follows:
Group I: patients with ocular GVHD submitted to alloge-
neic BMT;
Group II: patients without ocular GVHD submitted to au-
tologous and allogeneic BMT.
All patients underwent a complete ocular examination
regarding the presence of ocular GVHD. The tear film was
evaluated using the rose bengal staining test, Schirmer test
and the tear breakup time (BUT). The rose bengal staining was
performed by instillation of one drop of 1% rose bengal (Oph-
thalmosâ, São Paulo). The intensity of the staining was esti-
mated using a grading system(9). Each eye was divided into
three zones and the amount of stain in each of them was
recorded according to a scale of 0 to 3. In that way a maximum
score of 9 was obtained. A value greater than 3 was
considered a positive test. Schirmer test was made using
strips from Alcon (Fortworth, TX) which were positioned at
the inferior fornix after instillation of one drop of anesthetic
0.5% proxymetacaine (Anestalconâ - Alcon), in each eye
during 5 minutes. Values lower than 4 mm of wetting were
considered abnormal(10). BUT values were measured after the
instillation of 0.25% sodium fluoresceine (Fluoresceinaâ,
Frumtost). A test was considered positive when dry spots were
seen at the slit lamp less than 10 seconds after blinking(11).
The presence of at least two positive tests associated with
the presence of characteristic symptoms were considered
diagnostic of keratoconjunctivitis sicca (KCS) and this was
the criterion used to define ocular GVHD. The following sym-
ptoms were considered related to dry eye: burning, foreign
body sensation, blurred vision, ocular pain, mucus discharge,
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tearing and photophobia. The following findings were consi-
dered signs of dry eye: typical changes on slit lamp examina-
tion, such as conjunctival hyperemia and punctate keratopa-
thy, and positive results of the lacrimal function tests for dry
eye described above.Hematologists from the Fundação Pró-
Sangue of São Paulo made the diagnosis of GVHD according
to the following criteria(3):
Classification scheme for patients with chronic GVHD
Limited chronic GVHD
Either or both:
1. Localized skin involvement
2. Hepatic dysfunction due to chronic GVHD
Extensive chronic GVHD
Either:
1. Generalized skin involvement; or
2. Localized skin involvement and/or hepatic dysfunction due
to chronic GVHD, plus:
a) Liver histology showing chronic aggressive hepatitis,
bridging necrosis or cirrhosis; or
b) Involvement of eye: Schirmer´s test with less than 5 mm
wetting; or
c) Involvement of minor salivary glands or oral mucosa
demonstrated on labial biopsy; or
d) Involvement of any other target organ.
The distribution of the diseases was as follows: non-Hodg-
kin lymphoma: 8 patients; Hodgkin lymphoma: 2 patients; mul-
tiple myeloma: 2 patients; acute myelogenous leukemia: 5
patients; chronic myelogenous leukemia: 21 patients; severe
aplastic anemia: 7 patients; breast carcinoma: 1 patient; testicle
carcinoma: 1 patient. The conditioning regimen varied accor-
ding to the type of disease, consisting of busulfan (Myleranâ -
Wellcome), cyclophosphamide (Enduxanâ - Abbott) or melfalan
(Alkeranâ - Wellcome).
For all diseases, patients undergoing allogeneic BMT re-
ceived GVHD prophylaxis, consisting of cyclosporine A (San-
dimunâ - Sandoz) from one day before BMT to 180 days or 40
weeks after BMT, depending on clinical manifestations of
GVHD; methotrexate (Methotrexateâ - Lederle) on days 1, 3
and 6 after BMT and methylprednisolone (Solumedrolâ - Up-
john) or prednisone (Meticortenâ - Schering-Plough), from
day 8 to day 72 after BMT depending on the clinical manifes-
tations of GVHD in each patient.
Ocular examination, clinical diagnostic tests for dry eye
and biopsies of conjunctiva and lacrimal gland were done in
the pre- and posttransplant periods by the first author. The
pretransplant procedures were performed from 30 to 10 days
before BMT to avoid the effect of drugs used as conditioning
regimen. The posttransplant examination and biopsies were
performed after a minimum of 100 days after BMT, for examina-
tion during the chronic phase of GVHD.
Biopsies were performed with topical 0.5% proxymetacaine
anesthetic drops. Specimens of 4 mm were harvested from the
superior conjunctiva adjacent to the limbus and from the lacri-
mal gland at its palpebral portion. Specimens were embedded
in OCT compound (“Tissue-freezing Medium”, Leica, Reichert
& Jung Productsâ, Germany), snap-frozen in liquid nitrogen
and stored at -70°C until they were transported to the Hilles
Immunology Laboratory at the Massachusetts Eye and Ear
Infirmary, Boston, MA, where they were ultimately processed
for immunostaining using the immunoperoxidase techni-
que(12). The primary antibodies (Immunotech, Inc., Westbro-
ok, ME) used were anti-CD3 (mature T cells), anti-CD4 (helper
T cells, Th), anti-CD8 (supressor-cytotoxic T cells, Ts/c) and
anti-CD 19 (B cells), all diluted 1:50.
Cells displaying a positive brown reaction on the cell sur-
face were counted in three representative power field (x 450)
readings with a 10 x 10 mm ocular grid, as shown in Figures 1
and 2. Cell counts were made in a masked fashion using an
American Optical Microstar 110 Light microscope (Buffalo,
NY) by two independent investigators.
Figure 1 - Lacrimal gland biopsy performed after allogeneic BMT –
arrows indicate CD8+ lymphocytes stained brown (immunoperoxidase
staining with Mab CD8) (100X)
Figure 2 - Lacrimal gland biopsy performed after allogeneic BMT –
arrows indicate CD4+ lymphocytes stained brown (immunoperoxidase
staining with Mab CD4) (100X)
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The protocol of this study was approved by the UNIFESP
Medical Ethics Committee.
Statistical Analysis - The signal test was used, whenever
possible, for the variables determined by the immunohisto-
chemistry examinations, looking for possible differences bet-
ween before and after Bone Marrow Transplant(13). Level of
significance was p £ 0.05 (5%).
RESULTS
Of the 47 patients undergoing ocular examination, 25
(53.2%) were males and 22 (46.8%) females. The average age
was 30 years, and the range was 11 to 57 years. Of the total
number of patients, 13 (27.7%) were submitted to autologous
BMT and 34 (72.3%) to allogeneic BMT. Of the 34 patients
submitted to allogeneic BMT, 28 (82.3%) developed chronic
GVHD in one or more organs and 6 (17.7%) did not present
GVHD. Of the 28 (82.4%) patients with chronic GVHD, 13
(46.4%) presented ocular GVHD and 15 (53.6%) did not. Of the
six patients without GVHD, one (16.7%) presented ocular
GVHD and five (83.3%) did not have dry eyes.
None of those 13 patients submitted to autologous BMT
presented ocular GVHD and 14 (41.2%) of 34 patients with
allogeneic BMT presented ocular GVHD.
All patients with ocular GVHD (Group I) had symptoms
and the most frequent were burning, foreign body sensation,
blurred vision and dryness (Table 1). Some of these symptoms
were also sporadically reported by 5 (15%) patients without
ocular GVHD (Group II).
The rose bengal test was one of the most sensitive in this
study and the Schirmer test presented a lower sensitivity than
the rose bengal test. The breakup time of the lacrimal film
(BUT) was highly specific as it was never positive in indivi-
duals without ocular GVHD (Table 1). The slit lamp examina-
tion was considered the gold standard as all patients of Group
I showed conjunctival hyperemia, associated with other fin-
dings, such as the existence of filaments, punctate keratitis
and tarsal scars.
The results of the immunohistochemical analysis are pre-
sented in Tables 2 and 3. In the conjunctiva and lacrimal gland
of patients presenting dry eye (with ocular GVHD),there was
an increase of CD3, CD4 and CD8 cells, respectively indicating
an increase of the T, Th/i lymphocyte population and sup-
pressor-cytotoxic T cells after the transplantation.
DISCUSSION
The frequency of ocular GVHD in our series (41.2%) was
lower than that reported by other authors, probably due to the
criteria we used to diagnose dry eye. We question the utility
of the Shirmer test for the diagnosis of chronic GVHD without
Table 2. Immunohistochemical results (median/range) of patients with ocular GVHD and without ocular GVHD submitted to allogeneic
BMT (Group I, 8 patients) and to autologous and allogeneic BMT (Group II, 11 patients)
Antibodies CD3 median/range CD4 median/range CD8 median/range CD19median/range
Biopsy site Ocular GVHD Ocular GVHD Ocular GVHD Ocular GVHD
No ocular GVHD No ocular GVHD No ocular GVHD No ocular GVHD
Conjunctiva 6.6 / 2.0 – 40.0 2.5 / 1.0 – 30.0 4.5 / 1.0 – 42.0 0 / 0 – 31.0
before BMT 5.0 / 0 – 38.0 2.0 / 0 – 22.0 4.0 / 0 – 15.0 0 / 0
Conjunctiva 21.5 / 6.0 – 129.0 8.5 / 0 – 75.0 11.5 / 1.0 – 77.0 0 / 0 – 34.0
after BMT 8.0 / 0 – 90.0 3.0 / 0 – 58.0 11.0 / 0 – 31.0 0 / 0 – 56
Lacrimal gland 4.5 / 0 – 48.0 2.5 / 0 – 21.0 2.5 / 0 – 35.0 0 / 0
before BMT 6.5 / 0 – 38.0 6.0 / 0 – 31.0 8.0 / 0 – 17.0 0 / 0 – 1.0
Lacrimal gland 12.0 / 0 – 63.0 15.0 / 1.0 – 42.0 10.5 / 0 – 40.0 0 / 0
after BMT 10.0 / 0 – 134.0 4.0 / 0 – 88.0 5.0 / 0 – 33.0 0 / 0 – 8.0
Table 1. Number of patients with ocular GVHD (Group I) and without
ocular GVHD (Group II) presenting symptoms and signs of dry eye
Patients Symptoms RB ST BUT Slit lamp
Group I 14 13 9 10 14
(14 patients) (100%) (93%) (64%) (71%) (100%)
Group II 5 1 1 0 1
(33 patients) (15%) (3%) (3%) (3%)
Total 19 14 10 10 15
(47 patients) (40%) (30%) (21%) (21%) (32%)
RB = positive rose bengal test; ST = positive Schirmer test; BUT = positive tear
breakup test; Slit lamp = dry eye signs present on slit lamp examination
47 patients
13 (27.7%) autologous 34 (72.3%) allogeneic
28 (82.3%) 6 (17.7%)
chronic GVHD no GVHD
13 (46.4%) 1 (16.7%)
ocular GVHD ocular GVHD
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other manifestations such as symptoms, abnormalities in the
lacrimal function or at the slit-lamp examination(14).
One patient of our series, in spite of not presenting syste-
mic GVHD, had dry eye according to our criteria. Ocular mani-
festations may be the first presentation of GVHD and they
may be seen in the absence of systemic manifestations of
GVHD. Dry eyes can occur in patients without GVHD (15), pro-
bably as a result of total body radiation but other authors(14,16)
disagree. In a group of patients without chronic GVHD(14) 10%
had a positive Schirmer test, ocular symptoms and an abnor-
mal slit-lamp examination and none of them, as our patient, had
received radiation.
Ocular GVHD symptoms can easily be missed while the
patient shows already important ocular lesions at the first
ophthalmological examination (16). Focusing on the many life-
threatening problems present in this group of patients may
explain why the ocular complications are seen with such a
delay.
It is also possible that patients without systemic GVHD,
but with ocular GVHD, could be suffering lymphocytic infiltra-
tion also in other organs such as liver or skin, but at the time
they were examined they were not presenting clinical manifes-
tations yet. As the ocular GVHD has an autoimmune origin,
the immunohistochemical alterations should occur earlier, be-
fore clinical manifestations, so probably in the present study
the time of ocular examinations and biopsy could influence the
results. In these cases, the immunohistochemical examination
could be useful for an early diagnosis of ocular GVHD.
The symptoms of patients with ocular GVHD present in this
study are in accordance with studies by other authors(7,15), who
suggested that the clinical picture was very similar to that
present in patients with KCS either idiopathic or secondary to
Sjögren’s syndrome.
Dry eye in patients submitted to autologous BMT were
mentioned (17), attributing the alterations to total body irradia-
tion (TBI) or to the conditioning regimen. None of the patients
of this study submitted to autologous BMT developed dry
eye. A patient of this group mentioned ocular burning, and
another, submitted to TBI a year prior to BMT, complained
about ocular pain and tearing. However, their ocular examina-
tion did not show all diagnostic characteristics of ocular
GVHD. This difference in findings compared to those by other
authors(17) can be explained by the time elapsed between the
irradiation and ocular examination.
The most used clinical tests of lacrimal function reported
in the literature to evaluate patients after BMT are Schirmer
test and slit lamp(15). The slit lamp examination was very useful
in the evaluation of corneal and conjunctival alterations, since
these alterations were always present in patients with dry eye
in our study, as they were in other series(17). The rose bengal
test, in spite of rarely being mentioned in the literature in the
evaluation of patients with ocular GVHD, was one of the most
sensitive in this study (Table 1). The Schirmer test, in spite of
the fact that it presented a lower sensitivity than the rose
bengal test, has the advantage that it can be used by general
practitioners and hematologists, as part of propaedeutic eva-
luation of ocular GVHD, since it is not dependent on slit lamp
observation. However, when applied alone, it is not enough
for the diagnosis of dry eye, eventually resulting in conflic-
ting information(18).
The development of techniques with monoclonal antibo-
dies against T human cells and subpopulations has made the
functional differentiation of these lymphocytes possible and
contributed to the knowledge of the immunological composi-
tion of the inflammatory infiltrates. Monoclonal antibodies
were used to study the lymphocyte subpopulation in the
conjunctiva (12). These authors observed the predominance of
B cells in the normal conjunctival stroma in relation to T cells,
Ts/c cells being predominant over Th/i cells. The same subpo-
pulation was analyzed (19) and different populations from tho-
se previously described were found: T cells were predominant
over B cells 20 times.
In this research, analyzing the average conjunctival lym-
phocyte population of patients before being submitted to
BMT (Table 2), a greater number of cells was observed with
CD3 antigens (T lymphocytes) as opposed to the CD19 anti-
Table 3. Trend of variation in the number of cells stained with primary antibodies in the conjunctiva of patients with ocular GVHD (Group I;
n = 8), in the conjunctiva without ocular GVHD (Group II; n = 11), in the lacrimal gland of patients with GVHD (Group I; n = 8) and in the lacrimal
gland without GVHD (Group II; n = 11)  before and after transplantation
Conjunctiva - ocular GVHD Conjunctiva – non ocular GVHD
Antibodies Variation Significance Antibodies Variation Significance
CD3 8 ­ 0 ¯ 0 Æ p = 0.004 * CD3 5 ­ 2 ¯ 4 Æ p = 0.227 (NS)
CD4 7 ­ 1 ¯ 0 Æ p = 0.035 * CD4 5 ­ 3 ¯ 3 Æ p = 0.363 (NS)
CD8 6 ­ 0 ¯ 2 Æ p = 0.016 * CD8 5 ­ 2 ¯ 4 Æ p = 0.227 (NS)
CD19 1 ­ 0 ¯ 7 Æ       NA CD19 4 ­ 1 ¯ 6 Æ p = 0.188 (NS)
Lacrimal gland - ocular GVHD Lacrimal gland - non ocular GVHD
Antibodies Variation Significance Antibodies Variation Significance
CD3 7 ­ 0 ¯ 1 Æ p = 0.008 * CD3 4 ­ 3 ¯ 4 Æ p = 0.500 (NS)
CD4 7 ­ 0 ¯ 1 Æ p = 0.008 * CD4 5 ­ 3 ¯ 3 Æ p = 0.363 (NS)
CD8 7 ­ 1 ¯ 0 Æ p = 0.062 NS CD8 4 ­ 5 ¯ 2 Æ p = 0.500 (NS)
CD19 1 ­ 0 ¯ 7 Æ        NA CD19 3 ­ 0 ¯ 8 Æ          NA
Signal test: ­ = increase; ¯ = decrease; Æ = no variation; * = significant; NS = nonsignificant; NA = not analyzed
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gens (B lymphocytes), according other data(19). We compared
our data with those by other authors, in spite of our patients
having received aggressive treatment before BMT, because at
the moment they were examined and biopsied they were free of
malignant diseases on clinical and laboratory evaluation.
In the normal lacrimal gland, the T cells are present in a
larger number than B cells, with Ts/c cells predominanting
over Th/i cells(20-21). In the present study, on average, in pati-
ents before transplantation, the lymphocyte population of the
lacrimal gland was also observed to have a tendency of a
higher number of T than B cell population (Table 3).
The lymphocyte infiltrates that accumulate in lacrimal tis-
sue of patients with Sjögren’s syndrome and promote des-
truction of its tubular acinous architeture appear to be prima-
rily composed of B cells, disposed in clusters, and they tend
to be surrounded by Th/i cells(22-23). The Ts/c cells comprise a
small part of the mononuclear infiltrate, the presence of macro-
phages being rarer. A decreased reflex tearing is associated
with lymphocytic infiltration in lacrimal glands in patients with
Sjögren syndrome and dry eyes(24).
There is no reported research on immunohistochemistry of
the lacrimal gland of patients with GVHD. According to the
present study, in contrast to what occurred in patients with
Sjögren’s syndrome, the T cell population of patients with
ocular GVHD exceeded the B cells in the lacrimal gland and the
median of Th/i cells was approximately equal to that of Ts/c
cells (Table 2). These findings are in agreement with the obser-
vation that the effector primary cells in the affected tissues of
patients with GVHD are T cells(25).
The proportions of infiltrating lymphocyte subsets in the
labial salivary glands of patients with chronic GVHD suffering
from xerostomia were measured (26) and it was found that more
than 90% of the infiltrating lymphocytes were T cells with a
slight predominance of Ts/c over Th/i. In patients with Sjö-
gren’s syndrome, Th/i cells were predominant.
An immunohistochemical study of the conjunctiva of six
patients with ocular GVHD was performed and it was observed
that in the epithelium and in the conjunctival stroma there was a
larger number of Th/i cells as opposed to cells found in the
conjunctiva of three normal patients(27). It was concluded that
the conjunctiva also participates in the T cell mediated immuno-
logical reaction in ocular GVHD. Our data are in agreement with
the latter(27) and disagree with others(12), who found a larger
amount of Ts/c cells than Th/i cells in the conjunctiva, but their
conclusion was based on only one patient with GVHD.
In this research, the data shown in Tables 3 and 4 suggest
the existence of a cell mediated immunologic mechanism in the
conjunctiva and lacrimal gland of posttransplantation patien-
ts. This lymphocytic infiltration may explain the clinical pictu-
re of keratoconjunctivitis sicca secondary to GVHD. The des-
truction of the lacrimal gland tissue by lymphocytic cells was
reported(22) and it was also suggested (24) in patients with Sjö-
gren’s syndrome.
There are some variables involved in the analysis of this
study, such as the size of the sample, consideration of the
conjunctival tissue as a whole, and not separately as epithe-
lium and stroma, as done by other authors(12,21). But absolute
cellular counts vary from specimen to specimen, with relative
amounts of the different populations having to be taken into
account. Other variables, such as the use of immunosuppres-
sors, the time elapsed between the transplantation and the
biopsy, or even the interpretation of the immunohistochemis-
try results can have an influence on the results.
Most patients submitted to allogeneic BMT, presenting
ocular GVHD, were receiving immunosuppressive medication
at the time of the ocular examination and posttransplantation
biopsy. It is probable that there was an effect on immunohisto-
chemical results related to the use of cyclosporine A (the
medication administered for GVHD prophylaxis), since this
drug has a positive selective suppressive effect on T lympho-
cytes, especially Th/i(28). This drug would reduce the Th/i
population in patients submitted to BMT, explaining why, in
cases of GVHD, its population equaled that of Ts/c and was
not greater, as in Sjögren’s syndrome. A study comprising a
larger number of patients would be necessary for the confir-
mation of these results, comparing groups under and without
the effect of cyclosporine.
Recent improvements in the systemic management of pa-
tients with GVHD have led to the more frequent recognition of
the ocular problems. The high prevalence and potentially
severe ocular problems in these patients requires close oph-
thalmic monitoring. It can be assumed that in the future, with
the improvement and reduction in costs of immunohistoche-
mical techniques, the biopsy could also be useful promoting
early diagnosis of chronic GVHD, always accompanied by
ophthalmologic examination in addition to the Schirmer test
already performed today.
ACKNOWLEDGMENTS
To Dr Hanna A. Rothschild, medical editor, for the manus-
cript revision.
To Dr Tong Zhen Zhao, immunologist of Hilles Labora-
tory, Harvard Medical School, who helped me with the immu-
nohistochemistry technique.
ABSTRACT
Purpose: The primary ocular targets of chronic graft-versus-
host disease (GVHD) are the lacrimal gland (LG) and the con-
junctiva, and their involvement results in keratoconjunctivitis
sicca (KCS). The purpose of the present study was to evaluate
the frequency of signs and symptoms of KCS present in pa-
tients submitted to BMT, to identify the cellular phenotype of
the conjunctival and lacrimal gland biopsies of these patients
by immunohistochemistry and to correlate the findings with
the presence of dry eye due to GVHD. Methods: Forty-seven
patients were clinically classified into two groups: Group I,
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with ocular GVHD, submitted to allogeneic BMT and Group II,
without ocular GVHD, submitted to autologous and allogeneic
BMT. Thorough eye examination, including clinical lacrimal
function tests and biopsies of the conjunctiva and of the LG
were performed in the pre- and posttransplantation period.
The biopsies were submitted to immunohistochemical analy-
sis using a panel of monoclonal antibodies. Results: Of the 28
(82.4%) patients with chronic GVHD, 13 (46.4%) presented
ocular GVHD. Of the six patients without GVHD, one (16.7%)
presented ocular GVHD. None of those submitted to autolo-
gous BMT presented ocular GVHD and 14 (41.2%) of 34 pati-
ents with allogeneic BMT presented ocular GVHD. All patien-
ts with ocular GVHD (Group I) had symptoms and the most
frequent were burning, foreign body sensation, blurred vision
and dryness. The rose bengal test was one of the most sensi-
tive in this study and slit lamp examination was very useful in
the evaluation of corneal and conjunctival alterations, since
these alterations were always present in patients with dry eye
in our study. Neither symptoms and signs of dry eye nor
significant immunologic reaction was observed in the con-
junctiva and in the LG of patients without ocular GVHD
(Group II). There was an increase in the T lymphocyte popula-
tion, of T helper lymphocyte (Th/i) and T suppressor-cytoto-
xic lymphocyte (Ts/c) subpopulation in the conjunctiva and in
the LG of patients with ocular GVHD after the transplantation.
Conclusions: Patients submitted to allogeneic BMT may
develop ocular GHVD characterized by KCS. The immunohis-
tochemical study of the conjunctiva and lacrimal gland biop-
sies of these patients suggested that these tissues are the
target of the T cell mediated immunological reaction.
Keyword: Immunohistochemistry; Conjunctiva; Lacrimal appa-
ratus; Bone marrow transplantation/adverse effects; Graft vs
host disease
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